Milrinon Stragen (Milrinone)

Milrinone blocks phosphodiesterase‑3, which raises intracellular cyclic AMP levels in heart muscle and vascular smooth‑muscle cells. The increased cAMP enhances calcium entry, producing stronger heart contractions (positive inotropy) and causes vasodilation, lowering vascular resistance.

The dosing regimen for Milrinon Stragen is determined by the prescribing clinician based on the patient’s clinical condition, weight, renal function, and response to therapy. Only a qualified healthcare professional should set the infusion rate and duration.

Safety data for milrinone in pregnancy and lactation are limited, and the product is generally not recommended for use unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case individually.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Milrinone differs from catecholamine inotropes such as dopamine or dobutamine by providing both inotropic support and vasodilation through phosphodiesterase‑3 inhibition. This dual action can reduce afterload, whereas catecholamines primarily increase contractility and may raise heart rate and systemic vascular resistance.

Milrinon Stragen should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the solution in its original packaging until use, and discard any product that appears discolored or contains particles.

Milrinon Stragen is given as an intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed by qualified healthcare personnel in a monitored setting such as an intensive care unit.

The most serious risks include severe hypotension, life‑threatening ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Continuous hemodynamic monitoring is essential to detect and manage these complications promptly.

Milrinon Stragen is contraindicated in patients with known hypersensitivity to milrinone, severe aortic stenosis, uncontrolled arrhythmias, or those receiving other potent vasodilators that could cause dangerous drops in blood pressure. Clinicians must assess each patient’s medical history before initiating therapy.